Merck Ends Development of Blood Cancer Drug Nemtabrutinib
Merck is ending clinical development of nemtabrutinib, which was being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia and other blood cancers.
Merck is ending clinical development of nemtabrutinib, which was being evaluated for chronic lymphocytic leukemia, small lymphocytic leukemia and other blood cancers.